Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Return on Sales (2016 - 2025)

Editas Medicine (EDIT) has disclosed Return on Sales for 11 consecutive years, with 3.33% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 101529.0% to 3.33% in Q3 2025 year-over-year; TTM through Sep 2025 was 4.26%, a 85.0% decrease, with the full-year FY2024 number at 7.34%, down 540.0% from a year prior.
  • Return on Sales was 3.33% for Q3 2025 at Editas Medicine, up from 14.39% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.31% in Q4 2023 to a low of 1326.83% in Q3 2022.
  • A 5-year average of 146.53% and a median of 8.73% in 2021 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -132052bps in 2022, then surged 131840bps in 2023.
  • Editas Medicine's Return on Sales stood at 3.32% in 2021, then crashed by -180bps to 9.29% in 2022, then skyrocketed by 97bps to 0.31% in 2023, then tumbled by -372bps to 1.48% in 2024, then crashed by -124bps to 3.33% in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Return on Sales are 3.33% (Q3 2025), 14.39% (Q2 2025), and 16.24% (Q1 2025).